#1 Clinical Trials Search in Europe

Risdiplam

Risdiplam is an investigational drug being studied in clinical trials for the treatment of spinal muscular atrophy (SMA), a rare genetic disorder affecting muscle strength and movement. These trials aim to evaluate the safety, effectiveness, and proper dosing of risdiplam in infants, children, and adults with different types of SMA. The studies examine how risdiplam affects motor function, survival, breathing, and other important outcomes in SMA patients.

Table of Contents

What is Risdiplam?

Risdiplam, also known by its brand name Evrysdi[1], is a medication used to treat spinal muscular atrophy (SMA). SMA is a rare genetic disorder that affects muscle strength and movement[1]. Risdiplam is an orally administered drug, which means it can be taken by mouth, making it more convenient for patients compared to other treatments that require injections or infusions[2].

How Does Risdiplam Work?

Risdiplam works by modifying a process in the body called SMN2 pre-mRNA splicing. This process helps increase the levels of a protein called SMN (survival motor neuron) in the central nervous system and other tissues throughout the body[3]. The SMN protein is essential for the proper functioning of motor neurons, which are nerve cells that control muscle movement. In people with SMA, there’s not enough of this protein, which leads to muscle weakness and wasting. By increasing SMN protein levels, Risdiplam aims to improve muscle function and overall motor skills in patients with SMA[2].

What Conditions Does Risdiplam Treat?

Risdiplam is specifically designed to treat spinal muscular atrophy (SMA). SMA is a genetic condition that affects the motor neurons, which are nerve cells in the spinal cord that control muscle movement. There are different types of SMA, ranging from Type 1 (the most severe) to Type 4 (the mildest). Risdiplam has been studied and used in various types of SMA, including:

  • Type 1 SMA in infants[2]
  • Type 2 SMA in children and adults[4]
  • Presymptomatic SMA in infants (diagnosed before symptoms appear)[5]

The U.S. Food and Drug Administration (FDA) has approved Risdiplam for use in SMA patients aged 2 months and older[6]. This broad approval allows for treatment across various age groups and SMA types.

Administration and Dosage

Risdiplam is administered orally, which means it’s taken by mouth. This is a significant advantage over other SMA treatments that require injections or surgical procedures. The dosage of Risdiplam is typically adjusted based on the patient’s age and weight[7]. Here are some key points about its administration:

  • It’s usually taken once daily[1]
  • The dose may be adapted as the patient grows or gains weight[7]
  • Treatment duration can vary, with some clinical trials following patients for up to 5 years or more[1]
  • In some cases, Risdiplam may be given to infants as young as a few days old[8]

Always follow your doctor’s instructions regarding the dosage and administration of Risdiplam.

Clinical Trials and Effectiveness

Numerous clinical trials have been conducted to evaluate the effectiveness of Risdiplam in treating SMA. These trials have shown promising results across different age groups and SMA types. Some key findings include:

  • Improved motor function: Many patients showed improvements in their ability to sit, stand, or walk, depending on their SMA type and severity[2]
  • Increased survival: Studies have shown that Risdiplam can increase the chances of survival in infants with Type 1 SMA[2]
  • Better respiratory function: Some patients experienced improvements in their breathing abilities[2]
  • Enhanced daily living skills: Many patients showed improvements in activities like feeding and swallowing[2]

It’s important to note that the effectiveness of Risdiplam can vary from person to person, and not all patients may experience the same level of improvement.

Safety and Side Effects

Like all medications, Risdiplam can cause side effects. Clinical trials have been monitoring the safety of this drug closely. Here are some important points about its safety profile:

  • Common side effects: These may include fever, diarrhea, rash, or headache[3]
  • Serious side effects: While rare, more serious side effects can occur. These are closely monitored in clinical trials[3]
  • Long-term safety: Studies are ongoing to assess the long-term safety of Risdiplam, with some trials following patients for up to 5 years or more[1]
  • Ophthalmological effects: Regular eye examinations may be recommended as part of the treatment plan[5]

It’s crucial to report any side effects or concerns to your healthcare provider promptly.

Special Considerations

There are several special considerations to keep in mind regarding Risdiplam treatment:

  • Pregnancy and breastfeeding: The safety of Risdiplam during pregnancy or while breastfeeding is not well established. Discuss this with your doctor if you’re pregnant or planning to become pregnant[9]
  • Liver function: Some studies have looked at how liver function affects the processing of Risdiplam in the body. If you have liver problems, your doctor may need to adjust your dosage[9]
  • Combination with other treatments: Research is ongoing to understand how Risdiplam works in patients who have previously received other SMA treatments[7]
  • Growth and development: For children receiving Risdiplam, regular monitoring of growth and development is important[2]

Always consult with your healthcare provider about any concerns or questions you have regarding Risdiplam treatment. They can provide personalized advice based on your specific situation and medical history.

Aspect Details
Drug Name Risdiplam (also known as RO7034067, Evrysdi)
Condition Studied Spinal Muscular Atrophy (SMA)
Administration Oral, once daily
Patient Population Infants, children, and adults with various types of SMA
Key Outcome Measures Motor function, motor milestones, survival, ventilation needs, feeding ability
Safety Assessments Adverse events, laboratory tests, ophthalmological exams
Study Durations Typically 2 years or more, some with long-term extensions
Special Populations Presymptomatic infants, patients with hepatic impairment

FAQ

  • What is risdiplam and how does it work? Risdiplam is an oral medication that modifies the splicing of SMN2 pre-mRNA to increase production of functional SMN protein, which is deficient in people with SMA. It is designed to distribute throughout the body, including the central nervous system and peripheral tissues.
  • What types of SMA patients are being studied in risdiplam clinical trials? The clinical trials are studying risdiplam in infants, children, and adults with various types of SMA, including presymptomatic infants, patients with Type 1 SMA (the most severe form), and patients with Type 2 SMA. Some trials also include patients previously treated with other SMA therapies.
  • What are the main outcomes being measured in these trials? Key outcomes include motor function (assessed by scales like CHOP-INTEND and BSID-III), achievement of motor milestones (like sitting and walking), survival, need for ventilation, ability to swallow/feed, and safety measures. Some trials also look at biomarkers and drug concentrations in the body.
  • How is risdiplam administered in the trials? Risdiplam is given as an oral medication, typically once daily. The exact dose may be adjusted based on the patient's age and weight in some trials.
  • How long do the risdiplam clinical trials last? The duration varies between trials, but many last for 2 years or longer. Some trials include an open-label extension phase allowing participants to continue treatment for several additional years.

Ongoing Clinical Trials on Risdiplam

  • Study on the Safety and Pharmacokinetics of Risdiplam in Infants with Spinal Muscular Atrophy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Italy The Netherlands Norway Poland

  • Study on the Early Use of Risdiplam for Children with Spinal Muscular Atrophy After Gene Therapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Poland

  • Study on the Effectiveness and Safety of Risdiplam for Children with Spinal Muscular Atrophy After Gene Therapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Poland

  • Study of Risdiplam for Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland

  • Study on the Safety and Effects of Risdiplam for Adults and Children with Spinal Muscular Atrophy

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy The Netherlands Poland

  • Study on the Effects of Risdiplam in Adults with Spinal Muscular Atrophy Types 2 or 3 or with Up to 4 SMN2 Gene Copies

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Spinal Muscular Atrophy (SMA): A rare genetic disorder characterized by loss of motor neurons and progressive muscle wasting, often affecting a person's ability to walk, eat, and breathe.
  • SMN protein: Survival Motor Neuron protein, which is essential for the survival of motor neurons. People with SMA have a deficiency of this protein.
  • CHOP-INTEND: Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders, a scale used to assess motor function in infants with neuromuscular disorders.
  • BSID-III: Bayley Scales of Infant and Toddler Development, Third Edition, a standardized assessment used to evaluate development in young children.
  • Permanent ventilation: The need for breathing support for 16 or more hours per day continuously for more than 21 days, or tracheostomy.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical and physiological effects.
  • Open-label study: A type of clinical trial where both the researchers and participants know which treatment is being administered.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Presymptomatic: The stage before symptoms of a disease appear, often used in reference to infants genetically diagnosed with SMA who have not yet shown signs of the condition.

References

  1. https://clinicaltrials.gov/study/NCT05232929
  2. https://clinicaltrials.gov/study/NCT02913482
  3. https://clinicaltrials.gov/study/NCT03032172
  4. https://clinicaltrials.gov/study/NCT04256265
  5. https://clinicaltrials.gov/study/NCT03779334
  6. https://clinicaltrials.gov/study/NCT05522361
  7. https://clinicaltrials.gov/study/NCT05861986
  8. https://clinicaltrials.gov/study/NCT05808764
  9. https://clinicaltrials.gov/study/NCT03920865